Driving reinvestment in R&D for antibiotics and advocating their responsible use

WP1C: Antibiotic Valuation

LEADER
Academic: Ramanan Laxminarayan, University of Strathclyde, United Kingdom

PARTNERS:
J. Wesseler, D. Drabik (Wageningen University), T. Göschl, A. Leporowski (Heidelberg University), R. Cooke, A. Morton, T. Bedford, A. Colson, R. Millar, I. Megiddo (University of Strathclyde)

The private partners in DRIVE-AB are: AstraZeneca AB, GlaxoSmithKline Research & Development, F. Hoffmann-La Roche Ltd, MSD, Astellas Pharma Europe LTD, Pfizer Limited and Sanofi-Aventis Research & Development

OBJECTIVES:

  1. Quantify the economic consequences of AMR from the perspectives of patient, health care providers and society as a starting point for valuing new antibiotics
  2. Develop novel valuation models that will quantify the value of new antibiotics from the perspectives of patients, physicians, payers and society as a whole
  3. Evaluate the sensitivity of valuations to alternative models of new antibiotic incentives models and drug development.
  4. Implement the models developed in Aim 2 to provide broad estimates of economic value of effective antibiotics by categories of antibiotics to develop four valuation cases based on hypothetical new antibiotics
  5. Conduct extensive sensitivity analyses to test robustness of new antibiotics valuation to changes in regulatory and market environment

KEY MESSAGES

  1. The value of antibiotics in health care is greater than their value for treating infectious disease. Antibiotics also reduce the risk of common medical procedures (e.g., hip surgery and Caesarean sections), and they have option and diversity value.
  2. The value of different types of antibiotics will vary at different points in time depending on what the public health need is. For example, because we currently lack options for treating Gram-negative infections, a novel agent targeting these pathogens may have a higher societal value than an antibiotic which addresses easily treatable infections.
  3. New economic models and HTA guidelines are needed that better reflect the true value of antibiotics to patients, payers, and society.

DOWNLOADS & RESOURCES

For more detail about Package 1C progress, please see our past NEWSLETTERS.

To get involved as a stakeholder, see the group’s STAKEHOLDER ENGAGEMENT PAGE.

OUTPUTS

Publication: Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study